Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pharvaris N.V. (PHVS : NSDQ)

• Company Description    Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated indications. Pharvaris N.V. is based in ZUG, Switzerland. Number of Employees: 129

• Price / Volume Information    Yesterday's Closing Price: $29.68 Daily Weekly Monthly 20 Day Moving Average: 434,790 shares Shares Outstanding: 65.41 (millions) Market Capitalization: $1,941.31 (millions) Beta: -2.34 52 Week High: $33.33 52 Week Low: $15.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.76% 3.45% 12 Week 6.00% -2.01% Year To Date 6.95% 1.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL EMMY NOETHERWEG 2 - LEIDEN,P7 2333 NLD ph: 31-71-203-6410 fax: - info@pharvaris.com http://www.pharvaris.com

• General Corporate Information    Officers Berndt Modig - Chief Executive Officer and Director Stefan Abele - Chief Operations Officer David Nassif - Chief Financial Officer Hans Schikan - Director David Meeker - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N69605108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 65.41 Most Recent Split Date: (:1) Beta: -2.34 Market Capitalization: $1,941.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.25 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 37.34% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.02 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 21.35% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -67.56 12/31/25 - -70.96 09/30/25 - -65.79 ROA 03/31/26 - -61.13 12/31/25 - -64.18 09/30/25 - -59.83 Current Ratio 03/31/26 - 11.24 12/31/25 - 10.11 09/30/25 - 12.86 Quick Ratio 03/31/26 - 11.24 12/31/25 - 10.11 09/30/25 - 12.86 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.23 12/31/25 - 4.71 09/30/25 - 6.71 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.22 12/31/25 - 0.21 09/30/25 - 0.14

Powered by Zacks Investment Research ©